EDIT vs CRSP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRSP Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin, Momentum & Technical while EDIT counters with relative strength in Options & Structure. Fundamentally, EDIT trades at N/M Forward P/E with -167.0% operating margin (+37.4% YoY revenue) versus CRSP at 23.4x Forward P/E and -2058.6% operating margin (+1325.1% YoY). In options structure, EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro) against CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EDIT Revenue | CRSP Revenue | EDIT Op. Margin | CRSP Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | $0M | -356.1% | -5087.8% | EDIT |
| FY2019 | $20M | $290M | -686.4% | 16.1% | CRSP |
| FY2020 | $90M | $0M | -148.6% | -49295.5% | EDIT |
| FY2021 | $30M | $910M | -756.1% | 40.8% | CRSP |
| FY2022 | $20M | $0M | -1146.3% | -56190.4% | EDIT |
| FY2023 | $80M | $370M | -216.6% | -60.0% | CRSP |
| FY2024 | $30M | $40M | -777.2% | -1250.4% | EDIT |
| FY2025 | $40M | $0M | -394.9% | -18933.6% | EDIT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EDIT | CRSP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $336.5M | $4.1B | Larger Scale | CRSP |
| Trailing P/E Ratio Valuation | N/M | 23.4x | Lower Multiple | CRSP |
| Forward P/E Ratio Valuation | N/M | 23.4x | Lower Multiple | CRSP |
| Revenue Growth (YoY) Growth | +37.4% | +1325.1% | Higher Growth | CRSP |
| Operating Margin (TTM) Profitability | -167.0% | -2058.6% | Higher Margin | EDIT |
| Net Profit Margin Profitability | -144.9% | 0.0% | Higher Margin | CRSP |
| Return on Equity (ROE) Capital Efficiency | -147.4% | -25.6% | Higher ROE | CRSP |
| 52-Week Range Position Momentum | 11% ($2โ$4) | 1% ($40โ$63) | Stronger Trend | EDIT |
| Beta / 30D Volatility Risk Regime | 2.32ฮฒ ยท 102% Vol | 1.85ฮฒ ยท 60% Vol | Lower Realized Risk | CRSP |
| Unified Institutional Score Composite Signal | 48.4 / 100 (HOLD) | 44.7 / 100 (HOLD) | Higher Composite | EDIT |